Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
MERCK SHARP & DOHME CORP. v. SANDOZ INC.
Case Number:
3:12-cv-03289
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
August 20, 2015
Merck Wins Patent Dispute Over Cancer Treatment Drug
Following a bench trial, a New Jersey federal judge on Thursday validated Merck Sharp & Dohme Corp.'s patent for an anti-nausea drug used during chemotherapy, finding that its claims are not obvious and also determining that a proposed generic drug by Sandoz Inc. would infringe the patent.
-
February 15, 2013
Sandoz, Intas Can't Ditch Merck's Suit Over Generic Emend
A New Jersey federal judge on Thursday refused to strike a patent infringement claim from Merck Sharp & Dohme Corp.'s dispute with Sandoz Inc. and Intas Pharmaceuticals Ltd. over its anti-nausea drug Emend, ruling the court has proper jurisdiction over the claim.
-
June 05, 2012
Merck Targets Sandoz, Intas Over Generic Emend Plans
Merck Sharp & Dohme Corp. is suing Novartis AG unit Sandoz Inc. and India-based Intas Pharmaceuticals Ltd., claiming their plans to make a generic version of Merck's anti-nausea drug Emend would infringe two patents.